SCHEMBL4058909

SCHEMBL4058909

Fc1ccccc1Oc1ccc2c(-c3ccc(-c4cccnc4)cc3)n[nH]c2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.49
MAP2K4 P45985 5/20 0.48
LRRK2 Q5S007 2/20 0.48
IDO1 P14902 1/20 0.48
PIM1 P11309 5/20 0.47
TTK P33981 1/20 0.46
PIM2 Q9P1W9 2/20 0.46
PIM3 Q86V86 1/20 0.46
MAP2K7 O14733 2/20 0.45
CHEK1 O14757 2/20 0.43
PRMT5 O14744 1/20 0.43
WDR77 Q9BQA1 1/20 0.43
NTRK1 P04629 1/20 0.41
MKNK1 Q9BUB5 1/20 0.41
CLK2 P49760 1/20 0.40
CLK3 P49761 1/20 0.40
DYRK1A Q13627 1/20 0.40
FGFR1 P11362 1/20 0.40
CDK4 P11802 1/20 0.40
CCNA2 P20248 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4058556 0.90 MAP2K4 (0.59) AXLMAP2K4LRRK2IDO1TTK
SCHEMBL4059673 0.87 MAP2K4 (0.62) MAP2K4LRRK2IDO1TTKMAP2K7
SCHEMBL4057539 0.83 MAP2K4 (0.50) MAP2K4LRRK2MAP2K7CHEK1PRMT5
SCHEMBL4063638 0.83 MAP2K4 (0.50) MAP2K4LRRK2IDO1MAP2K7CHEK1
SCHEMBL4059067 0.83 MAP2K4 (0.50) MAP2K4LRRK2MAP2K7CHEK1NTRK1
SCHEMBL4061419 0.83 PDPK1 (0.56) MAP2K4LRRK2CHEK1FGFR1CDK4
SCHEMBL4063919 0.83 MAP2K4 (0.50) MAP2K4LRRK2MAP2K7CHEK1PRMT5
SCHEMBL4060287 0.80 MAP2K4 (0.49) MAP2K4LRRK2MAP2K7CHEK1PRMT5
SCHEMBL4061084 0.80 MAP2K4 (0.47) MAP2K4LRRK2MAP2K7CHEK1PRMT5
SCHEMBL4065232 0.79 MAP2K4 (0.48) MAP2K4LRRK2CHEK1PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495015-B2 Indazole derivatives and methods for using the same ROCHE PALO ALTO LLC (US) 2009-02-24 US claimed
EP-1747202-A1 INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM F.HOFFMANN-LA ROCHE AG (CH) 2007-01-31 EP claimed
US-20050215595-A1 Indazole derivatives and methods for using the same ROCHE PALO ALTO LLC 2005-09-29 US claimed
WO-2005085206-A1 INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM F. HOFFMANN-LA ROCHE AG (CH) 2005-09-15 WO claimed
US-7495015-B2 Indazole derivatives and methods for using the same ROCHE PALO ALTO LLC (US) 2009-02-24 US disclosed
US-7495015-B2 Indazole derivatives and methods for using the same ROCHE PALO ALTO LLC (US) 2009-02-24 US disclosed
US-7495015-B2 Indazole derivatives and methods for using the same ROCHE PALO ALTO LLC (US) 2009-02-24 US disclosed
US-20050215595-A1 Indazole derivatives and methods for using the same ROCHE PALO ALTO LLC 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215595-A1 Indazole derivatives and methods for using the same MAPK1, MAP3K1, MAP3K7 AXL 2173/4885MAP2K4 73/4885LRRK2 767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.